Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Key facts

Study ID: NCT06104839
Run by: NEXTGEN Bioscience
People needed: 73
Starts: 2024-09-01
Expected to finish: 2027-01-31
Last updated by the study team: 2026-04-13

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Men or women between ≥19 and ≤65 years of age at the time of informed consent
Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
Current episode of hair loss for ≥6 months but <8 years
Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

You may not qualify if…

Participants with the following medical history confirmed during screening:
ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors

Where it is running

Seoul National University Hospital. — Seoul, South Korea (enrolling)
Kyung Hee University Hospital at Gangdong — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.